Files
Abstract
For patients receiving Lu-DOTATATE therapy (four cycles every 8 weeks) for treatment of neuroendocrine tumors: does timing of laboratory assessment between treatment cycles have an impact on proportion of patients that must continue therapy at a reduced dose? And/or the proportion of patients that must postpone a subsequent infusion, or proportion of patients that must discontinue the therapy?